Appointment of Christian Chavy as Chief Executive Officer of Stallergenes

Appointment of Christian Chavy as Chief Executive Officer of Stallergenes

During its meeting held on March 5, 2014, the Board of Directors of Stallergenes announced the appointment of Christian CHAVY as Chief Executive Officer, to replace Roberto GRADNIK. This appointment will be effective on March 31, 2014.

The appointment of Christian CHAVY will enable the Group to pursue its strategy and to support Stallergenes in promising markets for immunotherapy, with a particular focus on the US market.

Roberto GRADNIK will ensure a smooth transition and will provide consultancy services to the Board of Directors during a four-month transitional period.

Patrick LANGLOIS, Chairman of the Board of Directors, commented: "On behalf of the Board of Directors, I would like to warmly thank Roberto GRADNIK, who has successfully implemented a new organization adapted to the new operational challenges faced by the Group. Under his leadership, the Group made a major breakthrough, with the preparation and submission of the application for commercial authorisation of Oralair® tablets in the US, which is currently reviewed by the FDA, and the definition of a long-term strategy, with a particularly strong focus on international markets. The appointment of Christian CHAVY represents a continuation of this strategy. His recognised management skills, his international experience and considerable knowledge of the pharmaceuticals industry will enable Stallergenes to continue its expansion into promising markets for immunotherapy and in particular to ensure the success of Oralair® in the US market."

In 2010, Christian CHAVY joined ARES Life Science, an investment fund dedicated to healthcare. Previously, he served as President of Global Operations for Actelion Pharmaceuticals (USA, Europe, Japan and rest of the world). Prior to joining Actelion, he was Vice President at the reproductive medicine strategic unit of Serono in Geneva and Chairman of Serono's French subsidiary. He also spent five years at Groupe Rhône Poulenc Rorer as its Chairman in Canada, having previously been Chairman and CEO of Rorer France. Christian CHAVY is a graduate of ESSEC and Institut de Contrôle de Gestion de Paris (ICG).

Suggested Articles

Pfizer and Astellas are chasing a new nod for prostate cancer drug Xtandi, and thanks to the FDA, they might not have to wait that long.

As AZ and FibroGen have yet to submit the novel anemia drug to the U.S. regulators, national reimbursement talks are already underway in China.

Health and Human Services, hoping to resurrect a rule that would force drug prices into TV ads, appealed a judge's decision that blocked it.